These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 16616348

  • 1. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.
    Rodriguez-Stanley S, Zubaidi S, Proskin HM, Kralstein JR, Shetzline MA, Miner PB.
    Clin Gastroenterol Hepatol; 2006 Apr; 4(4):442-50. PubMed ID: 16616348
    [Abstract] [Full Text] [Related]

  • 2. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia.
    Miner PB, Rodriguez-Stanley S, Proskin HM, Kianifard F, Bottoli I.
    Curr Med Res Opin; 2008 Aug; 24(8):2159-72. PubMed ID: 18561877
    [Abstract] [Full Text] [Related]

  • 3. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials.
    Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, Chey WD, Kralstein J, Earnest DL, Ligozio G, Cohard-Radice M.
    Am J Gastroenterol; 2008 Aug; 103(8):1906-19. PubMed ID: 18616658
    [Abstract] [Full Text] [Related]

  • 4. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
    Bardhan KD, Forbes A, Marsden CL, Mason T, Short G.
    Aliment Pharmacol Ther; 2004 Jul 15; 20(2):213-22. PubMed ID: 15233702
    [Abstract] [Full Text] [Related]

  • 5. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.
    J Gastroenterol Hepatol; 2007 Aug 15; 22(8):1183-9. PubMed ID: 17688659
    [Abstract] [Full Text] [Related]

  • 6. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.
    Am J Gastroenterol; 2008 May 15; 103(5):1217-25. PubMed ID: 18477346
    [Abstract] [Full Text] [Related]

  • 7. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
    Gut; 2005 Dec 15; 54(12):1707-13. PubMed ID: 16020489
    [Abstract] [Full Text] [Related]

  • 8. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J, Rüegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M.
    Am J Gastroenterol; 2002 Sep 15; 97(9):2321-7. PubMed ID: 12358251
    [Abstract] [Full Text] [Related]

  • 9. Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect.
    Majewski M, Jaworski T, Sarosiek I, Sostarich S, Roeser K, Edlavitch SA, Kralstein J, Wallner G, McCallum RW, Sarosiek J.
    Clin Gastroenterol Hepatol; 2007 Apr 15; 5(4):430-8. PubMed ID: 17445751
    [Abstract] [Full Text] [Related]

  • 10. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
    Khoshoo V, Armstead C, Landry L.
    Aliment Pharmacol Ther; 2006 Jan 01; 23(1):191-6. PubMed ID: 16393297
    [Abstract] [Full Text] [Related]

  • 11. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
    Fidelholtz J, Smith W, Rawls J, Shi Y, Zack A, Rüegg P, Lefkowitz M.
    Am J Gastroenterol; 2002 May 01; 97(5):1176-81. PubMed ID: 12014724
    [Abstract] [Full Text] [Related]

  • 12. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC, Barghout V, McBurney CR, Niecko TE.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):373-80. PubMed ID: 16128674
    [Abstract] [Full Text] [Related]

  • 13. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
    Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, Kalinin A, Dzieniszewski J, Haeck P, Fordham F, Hugot-Cournez S, Nault B.
    Am J Gastroenterol; 2005 Feb 01; 100(2):362-72. PubMed ID: 15667494
    [Abstract] [Full Text] [Related]

  • 14. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C.
    Int J Clin Pract; 2002 Feb 01; 56(1):47-51. PubMed ID: 11831835
    [Abstract] [Full Text] [Related]

  • 15. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.
    Zeng J, Zuo XL, Li YQ, Wei W, Lv GP.
    Eur J Clin Pharmacol; 2007 Jun 01; 63(6):529-36. PubMed ID: 17468863
    [Abstract] [Full Text] [Related]

  • 16. Features of gastroesophageal reflux disease in women.
    Lin M, Gerson LB, Lascar R, Davila M, Triadafilopoulos G.
    Am J Gastroenterol; 2004 Aug 01; 99(8):1442-7. PubMed ID: 15307857
    [Abstract] [Full Text] [Related]

  • 17. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb 01; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre.
    On Chan AO, Mo Hui W, Leung G, Hu WH, Lam SK, Wong BC.
    Aliment Pharmacol Ther; 2007 Feb 15; 25(4):463-9. PubMed ID: 17270002
    [Abstract] [Full Text] [Related]

  • 19. A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn.
    Rodriguez-Stanley S, Ciociola AA, Zubaidi S, Proskin HM, Miner PB.
    Aliment Pharmacol Ther; 2004 Nov 01; 20(9):975-82. PubMed ID: 15521845
    [Abstract] [Full Text] [Related]

  • 20. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia.
    Thumshirn M, Fruehauf H, Stutz B, Tougas G, Salter J, Fried M.
    Aliment Pharmacol Ther; 2007 Nov 15; 26(10):1399-407. PubMed ID: 17892526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.